Health-related quality of life in Crohn's disease: a prospective longitudinal study in 231 patients

Blondel-Kucharski, Fabienne; Chircop, Cécile; Marquis, Patrick; Cortot, Antoine; Baron, Florence; Gendre, Jean–Pierre; Colombel, Jean–Frédéric

doi:10.1111/j.1572-0241.2001.04681.x

Cited by 112 publications

(69 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A similar result was obtained in a smaller study using the French extended version of the RFIPC [35]. Five other studies have used multivariate techniques to identify RFIPC predictors [5,[28][29][30]36].…”

Section: Predictors Of the Rfipc Outcomesupporting

confidence: 76%

Worries and concerns in a large unselected cohort of patients with Crohn's disease

Stjernman

Tysk

Almér

et al. 2010

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

Section: Predictors Of the Rfipc Outcomesupporting

confidence: 76%

Worries and concerns in a large unselected cohort of patients with Crohn's disease

Stjernman

Tysk

Almér

et al. 2010

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

“…Autologous HSCT may replace hemolymphatic cells or their progenitor cells that generated the predisposing DNA sequence during ontogeny (e.g., T cell clones capable of recognizing the peptide) with healthy autologous hemolymphatic cells (e.g., T cell clones generated de novo in the thymus after HSCT that cannot recognize the peptide), thereby alleviating CD [14, 15]. The proposed mechanisms of autologous HSCT in the treatment of autoimmune diseases include immune suppression, immune resetting via repertoire replacement, and immune resetting via restoration of immune regulation [16].…”

Section: Discussionmentioning

confidence: 99%

Treatment of Crohn’s disease complicated with myelodysplastic syndrome via allogeneic hematopoietic stem cell transplantation: case report and literature review

Liu

et al. 2014

Clin J Gastroenterol

View full text Add to dashboard Cite

Crohn’s disease (CD) is a chronic inflammatory disease of the gastrointestinal tract arising in individuals with genetic predisposing factors and abnormalities of the immune system. Myelodysplastic syndrome (MDS), an acquired clonal hematologic disorder, is characterized by peripheral blood cytopenia, dysplastic changes in several types of hematopoietic cells of the bone marrow and peripheral blood, and a high risk of transformation to acute leukemia. CD rarely occurs in combination with MDS, and MDS treatment with hematopoietic stem cell transplantation (HSCT) has not been frequently reported. We report the case of a 50-year-old Chinese male who presented with abdominal pain, diarrhea, and fatigue. CD was diagnosed by colonoscopy, imaging studies, and pathological examination. He was initially treated with mesalazine and prednisone and thereafter he presented with pancytopenia. MDS (RAEB-I) was diagnosed by bone marrow examination, and karyotyping revealed 47, XY, +8. The patient was treated with thalidomide, andriol, and decitabine. Allogeneic HSCT was performed with a human leukocyte antigen-matched sibling as the donor. The patient is currently well at 14 months after HSCT, without abdominal pain, diarrhea, or fatigue. HSCT may be a promising treatment option for patients with combined CD and MDS.

show abstract

“…Crohn's disease (CD) is a chronic gastrointestinal disorder that negatively affects the quality of life of most patients with the disease 1. Data from population-based cohort studies show that the majority of patients experience a progressive course that transitions from pure inflammatory lesions to destructive complications such as stricture, fistula and abscess 2–4.…”

Section: Introductionmentioning

confidence: 99%

Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change

Ordás

Feagan

Sandborn

2011

Gut

113

View full text Add to dashboard Cite

Crohn's disease is a chronic inflammatory disorder that follows a progressive and destructive course. Ultimately, uncontrolled inflammation leads to bowel damage from disease-related complications such as strictures, fistulas and abscesses and surgical resection. Conventional 'step-care', whereby corticosteroids and immunosuppressives are prescribed sequentially, is an incremental approach to treatment that does not prevent disease progression and conveys an important risk of adverse events from repeated courses of corticosteroids. Although the immunosuppressives azathioprine, 6-mercaptopurine and methotrexate are corticosteroid-sparing, they are not highly effective for inducing mucosal healing or preventing disease progression. Tumour necrosis factor antagonists induce and maintain mucosal healing and reduce surgery and hospitalisation rates. This holds out the possibility that long-term use of these agents may prevent bowel damage. Combination therapy with immunosuppressives and tumour necrosis factor antagonists is likely the best strategy for achieving optimal outcomes in patients at high risk of disease progression. However, accurate prognostic markers must be identified to guide patient selection. Long-term prospective studies with robust outcomes are still needed to establish definitively the efficacy and safety of early combination therapy to prevent bowel damage, loss of gastrointestinal tract function and permanent disability.

show abstract

Health-related quality of life in Crohn's disease: a prospective longitudinal study in 231 patients

Abstract: Patients' QoL is impaired by CD and is underestimated by doctors. Tobacco, hospitalization, and use of corticoids have a negative impact on QoL. Conversely, the use of immunosuppressors is associated with a better QoL.

Cited by 112 publications

References 28 publications

Worries and concerns in a large unselected cohort of patients with Crohn's disease

Worries and concerns in a large unselected cohort of patients with Crohn's disease

Treatment of Crohn’s disease complicated with myelodysplastic syndrome via allogeneic hematopoietic stem cell transplantation: case report and literature review

Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change

Contact Info

Product

Resources

About